Pfizer lifts sales forecast for COVID-19 vaccine to $26 billion

Article feature image

(Reuters) – Pfizer Inc on Tuesday forecast $26 billion in COVID-19 vaccine sales this year, a more than 70% jump from its last projection, reflecting new contracts with governments around the world trying to halt the pandemic through rapid vaccination.

The raised goal assumes 1.6 billion doses of vaccine, which is co-developed with BioNTech SE, will be delivered in the year, with the two-shot vaccine emerging as the best-selling product for the U.S. drugmaker in the first quarter.

It is expected…

Click here to view the original article.

S&P/ASX 200 
7,014.20  31.50  0.45%  
ALL ORDINARIES 
7,239.40  30.40  0.42%  
Dow Jones Industrial Average 
34,382.13  360.73  1.06%  
S&P 500 
4,173.85  61.35  1.49%  
NASDAQ Composite 
13,429.98  304.98  2.32%  
NYSE COMPOSITE (DJ) 
16,415.36  233.76  1.44%  
FTSE 100 
7,043.61  80.28  1.15%  
DAX PERFORMANCE-INDEX 
15,416.64  216.94  1.43%  
Nikkei 225 
28,084.47  636.47  2.32%  
HANG SENG INDEX 
28,027.57  308.87  1.11%